Early Efficacy of Endostar Combined with Chemoradiotherapy for Advanced Cervical Cancers

Abstract

Asian Pacific J Cancer Prev, 13, 923-926 IntroductionCervical cancer is the most common gynecologic cancer. Surgery or radiotherapy can achieve satisfactory effect for early stage cervical cancer, while in the late stage (II b-IV a period) the main treatment therapy is radiation. At present, many studies all over the world reported that radiotherapy combined with chemotherapy can improve the survival rate of patients with cervical cancer. Concurrent chemoradiation, using cisplatin-based chemotheraphy (either cisplatin alone or cisplatin/5-fluorouracil), is the treatment of choice for stages Ib-IV a disease based on the results of many randomized clinical trials. (Lu et al., 2003;Dubay et al., 2004;Eifel et al., 2004; Duenas-Gonzale et al., 2011). These trials have shown that the use of Concurrent chemoradiation results in a 30%-50% decrease in the risk of death compared to RT alone. Although the optimal Concurrent chemotheraphy regimen to use with RT requires further investigation, these trails clearly established a role for Concurrent cisplatin-based chemoradiation. However, cervical cancer is not always sensitive to Chemoradiotherapy. As one of the malignant tumor, the similar angiogenesis and lymphangiogenesis happen in cervical cancer, and the density of blood vessels and lymphatic vessels is related with the malignancy and biological characteristics of the tumor. Therefore, it sounds reasonable to suppress tumor development by way of suppressing angiogenesis and lymphangiogenesis. Jia et al. (2009) AbstractThe aim of this study was to investigate the early outcome of Endostar combined with chemoradiotherapy for advanced cervical cancer. Fifty-two cases (FIGO Ⅱb to Ⅳa) were divided randomly into two groups, receiving chemoradiotherapy alone (CRT group) and Endostar combined with chemoradiotherapy (CRT+E group). For the patients in the CRT+E group, Endostar was administered daily with the dosage of 7.5 mg/m 2 , and cisplatin was administered weekly with the dosage of 20 mg/m 2 during the radiation. The regimens lasted for 4 weeks with no difference in chemoradiotherapy between the two groups. The early outcome complete remission rate was 73.1%, partial remission rate was 23.1% and the total response rate was 96.2% in CRT+E group, a significnat improvement on the 34.6%, 42.3% and 76.9%, respectively, in the CRT group. One year survive rates were 100% and 84.6% in the CRT+E group and CRT groups, the difference being significant. Endostar combined with chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and adverse effects were not encountered.

Efficacy and Safety of Endostar®Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

“…Endostar® can also inhibit human lung adenocarcinoma cell line SPC-A4. In addition, in in vitro experiments, results have showed that Endostar® can suppress the migration of HHEC,the formation of Tube, and the angiogenesis of Chorio Allantioc Membrane, and it can also suppress mouse tumor models (S180 sarcoma, H22 liver cancer ) and human xenograft tumor models (SPC-A4 lung adenocarcinoma, SGC7901 gastric cancer, HeLa cervical cancer, SMMC-7721 liver cancer and Bel7402 liver cancer) (Jia et al, 2012;Ke et al, 2012). In 2007, Endostar® became the first-line drug in the treatment of NSCLC.…”

The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

“…Furthermore, Endostar can suppress tumour growth in mouse models (S180 sarcoma, H22 liver cancer) and human xenograft models (SPC-A4 lung adenocarcinoma, SGC7901 gastric cancer, HeLa cervical cancer, SMMC-7721 and Bel7402 liver cancer). It has been reported that Endostar can suppress not only angiogenesis but also lymph node metastasis [16, 17]. The addition of Endostar results in significant improvement in response rate, median time to tumour progression, and clinical benefit rate in patients with advanced NSCLC [12, 18-20].…”

Salvage Therapy of Gemcitabine Plus Endostar Significantly Improves Progression-free Survival (PFS) with Platinum-resistant Recurrent Epithelial Ovarian Cancer

“…Endostar combining with chemoradiotherapy could improve the early outcome of the advanced cervical cancer, and adverse effects were not encountered (Ke et al, 2012). TC plus endostar seemed to improve ORR (39.3% vs. 23.0%) with a good safety profile in previous untreated advanced NSCLC, compared with TC alone (Han et al, 2011).…”